Pathology Presents: Potent Antibody-Based Conjugates for Cancer Therapy
This event has ended.
Peter Senter, PhD
Vice President, Chemistry
Senior Distinguished Fellow
- Faculty Sponsor
Eddie Fox, PhD
Potent Antibody-Based Conjugates for Cancer Therapy: From Early Stage Research to a Clinically Approved Drug
Monoclonal antibodies (mAbs) have played a major role in cancer medicine, with active drugs such as trastuzumab (Herceptin), cetuximab (Erbitux), bevacizumab (Avastin) and rituximab (Rituxan) in a wide range of therapeutic applications. The mechanisms of these agents involve such activities as direct signaling, interactions with Fc receptors on effector cells, and complement fixation. Several approaches have been explored to improve antibody-based therapies for cancer treatment by optimizing such activities and by conscripting their selectivity profiles for the delivery of high potency cytotoxic drugs. This latter area has advanced significantly in the past few years, with the approval of antibody drug conjugates such as Adcetris (brentuximab vedotin, SGN-35) for the treatment of relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. This presentation will describe how Adcetris was discovered and developed, and will also overview how antibody drug conjugate technology for cancer therapy is being extended to include new antigen targets, new drugs, and new conditionally-labile linkers. hypersensitivity pneumonitis, advanced pulmonary Langerhans cell histiocytosis, end-stage pulmonary sarcoidosis, Erdheim-Chester disease, and Hermansky-Pudlak syndrome) will be presented, each with detailed clinical, radiologic, and histopathologic attributes, emphasizing similarities to and differences from IPF.